Keros Therapeutics, Inc. (KROS) Financials

KROS Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 370.0 million 37.8 million
2023-09-30 326.2 million 30.4 million
2023-06-30 356.3 million 30.0 million
2023-03-31 384.4 million 29.5 million

KROS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -26.0 million 7.3 million
2023-09-30 -34.5 million 8.7 million
2023-06-30 -31.1 million 7.0 million
2023-03-31 -35.3 million 5.7 million

KROS Net Income

No data available :(

KROS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 331.1 million - 14.4 million
2023-09-30 287.9 million - 14.3 million
2023-06-30 322.0 million - 14.0 million
2023-03-31 351.4 million - 14.0 million

KROS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 30.1 million
2023-09-30 29.7 million
2023-06-30 29.6 million
2023-03-31 28.4 million

KROS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 541000 37.5 million 9.1 million -
2023-09-30 550000 34.1 million 9.1 million -
2023-06-30 311000 32.5 million 8.8 million -
2023-03-31 1.1 million 31.1 million 7.8 million -

KROS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 143000 247000
2023-09-30 8000 551000
2023-06-30 - 545000
2023-03-31 - 689000

KROS

Price: $57.72

52 week price:
27.02
73.00

Earnings Per Share: -5.20 USD

P/E Ratio: -11.92

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 412500

Market Capitalization: 2.1 billion

Links: